Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Watson Pharmaceuticals was founded in 1984 in Corona, California. The company has facilities across the USA, and in the UK and China. It vies with Barr and Mylan as the USA’s largest generic manufacturer.
Watson’s sales for 2009 stood at US$2,793.0 million, an increase of 10.2% over the US$2,535.5 million reported for 2008. Generic net revenues amounted to US$1,668.2 million, up by 13.2% over the US$1,474.3 million reported for 2008.
The company has always had a small branded business, introducing its first branded product in 1996. In February 2003, the FDA approved Oxytrol, the company’s oxybutin product. This is the first product Watson has fully developed from conception to manufacturing and distribution.
In March 2006, Watson announced it had entered into an agreement to acquire the outstanding stock of Andrx, in a deal worth some US$1.9 billion. The deal was completed in November 2006.
In June 2009, Watson announced plans to acquire the Arrow Group for US$1.75 billion in cash and stocks. The acquisition would give the firm commercial operations in over 20 countries. It closed in late 2009; Watson believes it will be a pivotal acquisition.